TY - JOUR
T1 - The anti-diabetic effect of eight
T2 - Lagerstroemia speciosa leaf extracts based on the contents of ellagitannins and ellagic acid derivatives
AU - Guo, Sen
AU - Ren, Xiameng
AU - He, Kan
AU - Chen, Xiaozhuo
AU - Zhang, Shanshan
AU - Roller, Marc
AU - Zheng, Bolin
AU - Zheng, Qunyi
AU - Ho, Chi Tang
AU - Bai, Naisheng
N1 - Funding Information:
The authors wish to thank the National Natural Science Foundation of China (No. 31570348) and Naturex Inc. for funding this project. The authors also wish to thank Ying Leng, Ying Feng, Xiao Liu, and Gendi You, Shanghai Institute of Materia Media, Chinese Academy of Sciences, Shanghai, China, for performing the antidiabetic in vivo bioassay. The authors also wish to thank Jaekyung Kim, Yanyan Cao, and Yi Liu, Edison Biotechnology Institute and Department of Biological Sciences, Ohio University, for performing the antidiabetic and adiposity bioassays.
Publisher Copyright:
© The Royal Society of Chemistry 2020.
PY - 2020/2
Y1 - 2020/2
N2 - Previously, we have reported the opposite effects of compounds isolated from Lagerstroemia speciosa leaves on a glucose transport (GLUT4) assay. Ellagitannins from L. speciosa activated GLUT4, while ellagic acid derivatives showed an inhibitory effect. As part of our continuing research on anti-diabetic nutritional supplements, we herein compared the anti-diabetic effects of several extracts (LE1-8) from leaves of L. speciosa using different manufacturing processes based on the contents of ellagitannins and ellagic acid derivatives. Their anti-diabetic effects were evaluated through glucose uptake and adipocyte differentiation in 3T3-L1 cells in vitro as well as alloxan induced diabetic mice in vivo. These extracts were given to mice by gavage at doses of 0.25, 1.0, and 4.0 g per kg body weight once a day for 21 consecutive days. Results showed that LE1 (1.0 g kg-1), LE3 (1.0 or 4.0 g kg-1), LE4 (1.0 or 4.0 g kg-1), LE5 (0.25 or 1.0 or 4.0 g kg-1) and LE7 (1.0 or 4.0 g kg-1) showed significant anti-diabetic effects in alloxan-induced diabetic mice as indicated by the decreased levels of fasting blood glucose, body weight, serum biomarkers, tissue weight and body fat, and increased final insulin levels. LE8 (1.0 g kg-1) showed a moderate anti-diabetic effect as illustrated by the reduced fasting blood glucose level while LE2 and LE6 showed slight effects in alloxan-induced diabetic mice. The potential correlation of the content of ellagitannins, ellagic acid derivatives, and corosolic acid with the anti-diabetic activity was discussed.
AB - Previously, we have reported the opposite effects of compounds isolated from Lagerstroemia speciosa leaves on a glucose transport (GLUT4) assay. Ellagitannins from L. speciosa activated GLUT4, while ellagic acid derivatives showed an inhibitory effect. As part of our continuing research on anti-diabetic nutritional supplements, we herein compared the anti-diabetic effects of several extracts (LE1-8) from leaves of L. speciosa using different manufacturing processes based on the contents of ellagitannins and ellagic acid derivatives. Their anti-diabetic effects were evaluated through glucose uptake and adipocyte differentiation in 3T3-L1 cells in vitro as well as alloxan induced diabetic mice in vivo. These extracts were given to mice by gavage at doses of 0.25, 1.0, and 4.0 g per kg body weight once a day for 21 consecutive days. Results showed that LE1 (1.0 g kg-1), LE3 (1.0 or 4.0 g kg-1), LE4 (1.0 or 4.0 g kg-1), LE5 (0.25 or 1.0 or 4.0 g kg-1) and LE7 (1.0 or 4.0 g kg-1) showed significant anti-diabetic effects in alloxan-induced diabetic mice as indicated by the decreased levels of fasting blood glucose, body weight, serum biomarkers, tissue weight and body fat, and increased final insulin levels. LE8 (1.0 g kg-1) showed a moderate anti-diabetic effect as illustrated by the reduced fasting blood glucose level while LE2 and LE6 showed slight effects in alloxan-induced diabetic mice. The potential correlation of the content of ellagitannins, ellagic acid derivatives, and corosolic acid with the anti-diabetic activity was discussed.
UR - http://www.scopus.com/inward/record.url?scp=85080875370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080875370&partnerID=8YFLogxK
U2 - 10.1039/c9fo03091c
DO - 10.1039/c9fo03091c
M3 - Article
C2 - 32003379
AN - SCOPUS:85080875370
VL - 11
SP - 1560
EP - 1571
JO - Food and Function
JF - Food and Function
SN - 2042-6496
IS - 2
ER -